BMS and AstraZeneca buy Amylin for $7bn
Tuesday, January 15, 2013 - 05:00
in Mathematics & Economics
Two pharma giants have teamed up to buy US biotech Amylin, responsible for the Byetta and Bydureon anti-diabetes brands
Updated by artificial intelligence Tue, 13 Jun 2023, 2:53:47 UTC Learn more
- Tell your friends
- Get science news via